Skip to main content

What's up with Nanopore Sequencing?

There hasn't been a peep out of Oxford Nanopore Technologies since the company announced in February that its DNA strand sequencing nanopore method is working and that it is developing it commercially. "When will nanopores actually hit the market?" asks Keith Robison at his Omics! Omics! blog.

A recent review article on nanopore sequencing by Meni Wanunu at Northeastern University questions "whether the remaining technical hurdles can be overcome to create a workable, easily produced commercial device," according to the publisher.

In a LinkedIn forum, DNA sequencing veteran Tim Hunkapillar ponders whether "it just may be that nanopore sequencers are the perpetual motion machines of our age."

But for Robison, "a more apt comparison would be to the world of nuclear power, and the question is whether nanopores are more akin to nuclear fission or nuclear fusion."

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.